Taysha Gene Therapies - TSHA Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $7.00
Forecasted Upside: 126.54%
Number of Analysts: 9
Breakdown:
0 Sell Ratings
0 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$3.09 As of 05/17/2024 01:00 AM ET

▼ -0.05 (-1.59%)

1 month | 3 months | 12 months

Get New Taysha Gene Therapies Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for TSHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TSHA

^$7.00

▲ +126.54% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $7.00, with a high forecast of $9.00 and a low forecast of $5.00. The average price target represents a 126.54% upside from the last price of $3.09.

Current Consensus is Buy

The current consensus among 9 polled investment analysts is to buy stock in Taysha Gene Therapies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/25/2022

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/23/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/24/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/22/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/20/2023

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/18/2024

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/18/2024

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/15/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$7.00	Low
5/15/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$7.00	Low
5/14/2024	Jefferies Financial Group	Reiterated Rating	Hold ➝ Buy	$2.00 ➝ $8.00	Low
5/2/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$7.00	Low
4/30/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$7.00	Low
4/18/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$7.00	Low
4/11/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$7.00	Low
4/9/2024	Piper Sandler	Initiated Coverage	Overweight	$9.00	Low
3/21/2024	Canaccord Genuity Group	Reiterated Rating	Buy ➝ Buy	$7.00	Low
3/21/2024	Chardan Capital	Boost Target	Buy ➝ Buy	$5.00 ➝ $7.00	Low
3/20/2024	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00	Low
3/20/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$7.00	Low
3/20/2024	Needham & Company LLC	Boost Target	Buy ➝ Buy	$5.00 ➝ $7.00	Low
2/29/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$5.00	Low
12/18/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$7.00	Low
11/15/2023	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$6.00 ➝ $7.00	Low
9/20/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$5.00	Low
9/20/2023	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$7.00 ➝ $6.00	Low
9/20/2023	Truist Financial	Lower Target	Buy ➝ Buy	$6.00 ➝ $5.00	Low
8/16/2023	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$13.00 ➝ $7.00	Low
8/15/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$4.00	Low
8/15/2023	Truist Financial	Boost Target	Buy ➝ Buy	$2.00 ➝ $6.00	Low
8/15/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$6.00 ➝ $5.00	Low
8/15/2023	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$5.00	Low
8/15/2023	Robert W. Baird	Boost Target	Outperform ➝ Outperform	$6.00 ➝ $8.00	Low
8/14/2023	Cantor Fitzgerald	Boost Target	Overweight ➝ Overweight	$2.00 ➝ $7.00	Low
3/30/2023	JMP Securities	Reiterated Rating	Market Outperform	$4.00	Low
3/30/2023	Cantor Fitzgerald	Lower Target	Overweight	$13.00 ➝ $2.00	Low
3/29/2023	Chardan Capital	Lower Target	Buy	$6.00 ➝ $5.00	Low
3/29/2023	Needham & Company LLC	Reiterated Rating	Buy	$6.00	N/A
3/29/2023	Truist Financial	Lower Target	Buy	$4.00 ➝ $3.00	Low
2/2/2023	BTIG Research	Downgrade	Buy ➝ Neutral		Low
2/1/2023	Canaccord Genuity Group	Lower Target	Buy	$17.00 ➝ $13.00	Low
2/1/2023	Cantor Fitzgerald	Reiterated Rating	Overweight	$24.00 ➝ $13.00	Low
2/1/2023	Truist Financial	Lower Target	Buy	$15.00 ➝ $4.00	Low
2/1/2023	Chardan Capital	Lower Target	Buy	$16.00 ➝ $6.00	Low
2/1/2023	JMP Securities	Lower Target	Market Outperform	$6.00 ➝ $4.00	Low
2/1/2023	Needham & Company LLC	Lower Target	Buy	$16.00 ➝ $6.00	Low
2/1/2023	Robert W. Baird	Lower Target	Outperform	$10.00 ➝ $6.00	Low
2/1/2023	Jefferies Financial Group	Downgrade	Buy ➝ Hold		Low
1/27/2023	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$23.00 ➝ $3.00	Low
1/19/2023	JMP Securities	Lower Target	Market Outperform	$20.00 ➝ $6.00	Low
1/4/2023	Wells Fargo & Company	Lower Target	Overweight	$14.00 ➝ $10.00	Low
12/21/2022	Cantor Fitzgerald	Reiterated Rating	Overweight		N/A
11/14/2022	Wells Fargo & Company	Lower Target		$20.00 ➝ $14.00	Low
11/10/2022	JMP Securities	Lower Target	Market Outperform	$22.00 ➝ $20.00	Low
11/10/2022	BTIG Research	Lower Target		$25.00 ➝ $15.00	Low
11/9/2022	Chardan Capital	Lower Target	Buy	$32.00 ➝ $16.00	Low
11/9/2022	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral		N/A
11/8/2022	Guggenheim	Lower Target		$22.00 ➝ $19.00	Low
11/8/2022	Needham & Company LLC	Lower Target	Buy	$18.00 ➝ $16.00	Low
11/8/2022	Canaccord Genuity Group	Initiated Coverage	Buy ➝ Buy	$16.00	Low
10/26/2022	Truist Financial	Lower Target		$35.00 ➝ $15.00	Low
10/26/2022	Robert W. Baird	Lower Target	Outperform	$26.00 ➝ $21.00	N/A
10/25/2022	Needham & Company LLC	Lower Target	Buy	$20.00 ➝ $18.00	Low
8/12/2022	Chardan Capital	Lower Target	Buy	$34.00 ➝ $32.00	Low
8/12/2022	Wedbush	Lower Target	Outperform	$9.00 ➝ $5.00	Low
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$27.00 ➝ $16.00	Low
5/17/2022	Chardan Capital	Lower Target		$37.00 ➝ $34.00	Medium
5/17/2022	Guggenheim	Lower Target	NA	$22.00	Low
5/17/2022	Needham & Company LLC	Lower Target	Buy	$20.00	Low
4/1/2022	Truist Financial	Lower Target	Buy	$60.00 ➝ $35.00	Medium
4/1/2022	Needham & Company LLC	Lower Target	Buy	$47.00 ➝ $32.00	Medium
4/1/2022	JMP Securities	Lower Target	Market Outperform	$44.00 ➝ $36.00	Medium
4/1/2022	The Goldman Sachs Group	Lower Target	Buy	$34.00 ➝ $27.00	Medium
3/31/2022	Chardan Capital	Lower Target		$60.00 ➝ $37.00	High
3/9/2022	Robert W. Baird	Initiated Coverage	Outperform	$26.00	High
3/1/2022	Wells Fargo & Company	Initiated Coverage	Overweight	$25.00	Low
2/18/2022	Sumitomo Mitsui Financial Group	Initiated Coverage	Outperform	$25.00	High
2/1/2022	JMP Securities	Reiterated Rating	Buy	$44.00	High
1/14/2022	JMP Securities	Reiterated Rating	Buy	$38.00	High
12/16/2021	Guggenheim	Initiated Coverage	Buy	$28.00	High
12/2/2021	Needham & Company LLC	Reiterated Rating	Buy	$47.00	High
11/11/2021	JMP Securities	Lower Target	Market Outperform	$40.00 ➝ $38.00	Medium
10/28/2021	JMP Securities	Reiterated Rating	Buy	$40.00	Low
10/6/2021	Needham & Company LLC	Boost Target		$45.00 ➝ $47.00	Low
9/24/2021	JMP Securities	Reiterated Rating	Buy	$40.00	Low
9/23/2021	William Blair	Reiterated Rating	Buy		High
8/31/2021	BTIG Research	Reiterated Rating	Buy	$44.00	Medium
8/31/2021	JMP Securities	Reiterated Rating	Buy	$40.00	Medium
8/18/2021	Morgan Stanley	Lower Target	Overweight	$43.00 ➝ $39.00	Medium
8/17/2021	Chardan Capital	Lower Target	Buy	$67.50 ➝ $60.00	High
7/15/2021	Needham & Company LLC	Initiated Coverage	Buy	$45.00	High
7/1/2021	Chardan Capital	Reiterated Rating	Buy		High
6/24/2021	Truist Financial	Initiated Coverage	Buy	$60.00	Medium
6/14/2021	BTIG Research	Initiated Coverage	Buy	$44.00	Low
6/9/2021	Wedbush	Initiated Coverage	Outperform	$31.00	Low
6/8/2021	JMP Securities	Initiated Coverage	Outperform	$40.00	Medium
5/19/2021	Cantor Fitzgerald	Initiated Coverage	Overweight	$44.00	Low
4/26/2021	Chardan Capital	Reiterated Rating	Buy		Medium
4/13/2021	Morgan Stanley	Boost Target	Overweight	$30.00 ➝ $43.00	High
4/12/2021	Chardan Capital	Boost Target	Buy	$60.00 ➝ $67.50	High
3/8/2021	Morgan Stanley	Boost Target	Overweight	$29.00 ➝ $30.00	High
3/4/2021	Chardan Capital	Boost Target	Buy	$45.00 ➝ $60.00	Low
2/23/2021	William Blair	Initiated Coverage	Outperform	$46.00	High
1/4/2021	Oppenheimer	Initiated Coverage	Outperform	$42.00	N/A
10/19/2020	Chardan Capital	Initiated Coverage	Buy	$45.00	High
10/19/2020	Jefferies Financial Group	Initiated Coverage	Buy	$34.00	High
10/19/2020	Morgan Stanley	Initiated Coverage	Overweight	$29.00	High
10/19/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$31.00	Medium

(Data available from 5/18/2019 forward)

News Sentiment Rating

0.37 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

1 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/21/2023

3 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/20/2023

3 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/20/2023

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/19/2024

1 very positive mentions
8 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/18/2024

10 very positive mentions
12 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/19/2024

8 very positive mentions
28 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/18/2024

5 very positive mentions
20 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

5/18/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Today's Range

Now: $3.09

$2.96

$3.14

50 Day Range

MA: $2.64

$2.13

$3.25

52 Week Range

Now: $3.09

$0.50

$3.89

Volume

970,609 shs

Average Volume

1,574,038 shs

Market Capitalization

$577.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Taysha Gene Therapies?: The following Wall Street analysts have issued stock ratings on Taysha Gene Therapies in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Jefferies Financial Group Inc., JMP Securities, Needham & Company LLC, Piper Sandler, Robert W. Baird, and Truist Financial Co..
View the latest analyst ratings for TSHA.
What is the current price target for Taysha Gene Therapies?: 9 Wall Street analysts have set twelve-month price targets for Taysha Gene Therapies in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 126.5%. Piper Sandler has the highest price target set, predicting TSHA will reach $9.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $5.00 for Taysha Gene Therapies in the next year.
View the latest price targets for TSHA.
What is the current consensus analyst rating for Taysha Gene Therapies?: Taysha Gene Therapies currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TSHA will outperform the market and that investors should add to their positions of Taysha Gene Therapies.
View the latest ratings for TSHA.
What other companies compete with Taysha Gene Therapies?: Other companies that are similar to Taysha Gene Therapies include Fate Therapeutics, Editas Medicine, Voyager Therapeutics, Allogene Therapeutics and Alector. Learn More about companies similar to Taysha Gene Therapies.
How do I contact Taysha Gene Therapies' investor relations team?: Taysha Gene Therapies' physical mailing address is 2280 Inwood Road, DALLAS TX, 75235. The company's listed phone number is 214-612-0000 and its investor relations email address is [email protected]. The official website for Taysha Gene Therapies is www.tayshagtx.com. Learn More about contacing Taysha Gene Therapies investor relations.

Taysha Gene Therapies - TSHA Stock Price Target and Predictions

Analyst Price Target for TSHA

Current Consensus is Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.37 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Taysha Gene Therapies?

What is the current price target for Taysha Gene Therapies?

What is the current consensus analyst rating for Taysha Gene Therapies?

What other companies compete with Taysha Gene Therapies?

How do I contact Taysha Gene Therapies' investor relations team?